Chest
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Asthma is a heterogenous disease with distinct clinical phenotypes, including the exacerbation-prone phenotype. This subset of patients contributes to disproportionately high morbidity, mortality and healthcare utilization among all asthma patients. We aimed to investigate the factors that are associated with frequent asthma exacerbations in patients with severe asthma. ⋯ The following authors have nothing to disclose: Jessica Tan, Mariko Koh, Anthony Yii, Adrian ChanNo Product/Research Disclosure Information.
-
Pediatric Pulmonary Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Extremly low birth weight (ELBW) is one of the main reason for neonatal intensive care. ELBW infants are at risc for developing respiratory distress syndrome (RDS), hypothermia, intraventricular hemorrhage and symptomatic persistant ductus arteriosus. Improper care at birth may worsen the symptomatology and the outcome of these prematures. ⋯ High frequency oscillatory ventilation should be the elective ventialtion mode in ELBW infants with RDS and/or pulmonary hemorrhage in order to get prompt respons and reduce major complicationsReference #1: Knobel R, Diane Holditch-Davis. Thermoregulation and Heat Loss Prevention After Birth and During Neonatal Intensive-Care Unit Stabilization of Extremely Low-Birthweight Infants. JOGNN May/June 2007. 36(3): 280-287.DOI: 10.1111/j.1552-6909.2007.00149.xReference #2: Cloherty, J., Eichenwald, E, Hansen AR, Stark, A.R, (Eds.). (2012). Manual of neonatal care (7th ed.). Philadelphia: Lippincott-Williams & Wilkins.Reference #3: AlKharfy T M. High-Frequency Ventilation in the Management of Very-Low-Birth-Weight Infants with Pulmonary Hemorrhage. Amer J Perinatol 2004; 21(1): 19-26. DOI: 10.1055/s-2004-820505DISCLOSURE: The following authors have nothing to disclose: Marta Simon, Manuela Cucerea, Zsuzsanna Gall, Monika Rusneac, Luminita Zahiu, Carmen Movileanu, Raluca Marian, Laura SuciuNo Product/Research Disclosure Information.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The etiology of bronchiectasis is varied with abnormal host defenses being one of the causes. We report the case of a 49-year-old male presenting with recurrent pneumonias. Imaging studies revealed bronchiectasis. Work up for bronchiectasis showed low immunoglobulin levels consistent with common variable immunodeficiency (CVID). The aim of this case report is to heighten awareness among physicians for the possibility of immunoglobulin deficiency in patients presenting especially with bronchiectasis, recurrent infections and sinus disease. ⋯ Among the various etiologies of bronchiectasis, the potentially treatable ones like CVID should never be missed. Appropriate and early institution of treatment can potentially improve survival, prevent deterioration of lung function and improve quality of life.Reference #1: Busse PJ, Farzan S, Cunningham-Rundles C, "Pulmonary complications of common variable immunodeficiency" Ann Allergy Asthma Immunol. 2007;98(1):1Reference #2: Park JH, Levinson AI,"Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)" Clin Immunol. 2010;134(2):97DISCLOSURE: The following authors have nothing to disclose: Khalid Sherani, Hineshkumar Upadhyay, Abhay Vakil, Kelly Cervellione, Craig ThurmNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Sustained bronchodilation is thought to contribute to the reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). Here we evaluate the effect of once-daily QVA149, a dual bronchodilator fixed-dose combination of indacaterol and glycopyrronium, on lung function and exacerbation rates in comparison with tiotropium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Angel FowlerTaylor: Employee: Novartis employee Peter D'Andrea: Employee: Novartis employee Christie Arrasate: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Joachim FickerNo Product/Research Disclosure Information.
-
An estimated 150,000 pulmonary nodules are identified each year, and the number is likely to increase given the results of the National Lung Screening Trial. Decision tools are needed to help with the management of such pulmonary nodules. We examined whether adding any of three novel functions of nodule volume improves the accuracy of an existing malignancy prediction model of CT scan-detected nodules. ⋯ The findings demonstrate that the addition of nodule volume to existing malignancy prediction models increases the proportion of nodules correctly classified. This enhanced tool will help clinicians to risk stratify pulmonary nodules more effectively.